BridgeBio to Present Additional Analyses from the Phase 3 ATTRibute-CM Trial of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy ( ATTR-CM ) at the ESC Congress 2024 and the HFSA Annual Meeting 2024 - BridgeBio Pharma ( NASDAQ:BBIO )
PALO ALTO, Calif., Aug. 29, 2024 ( GLOBE NEWSWIRE ) -- BridgeBio Pharma, Inc.
| Ticker |
Sentiment |
Impact |
|
BBIO
|
Somewhat Bullish
|
38 %
|
|
META
|
Neutral
|
10 %
|
